Fig. 2

METTL3 inhibits YTHDF2-mediated NLRC5 mRNA degradation. A m6Avar database of m6A modification on NLRC5 mRNA sequence and the very high confidence m6A site location (4808 and 5682) on NLRC5 mRNA sequence. B MeRIP-PCR data in HEC-1B cell shows the relative quantity of NLRC5 mRNA immunoprecipitated by the m6A antibody (m6A-IP) and IgG in cells with or without shMETTL3 (**P < 0.01 vs. shNC group), and the NLRC5 mRNA m6A modification site. C RIP-PCR data in Ishikawa cell with or without METTL3 overexpression shows the content of NLRC5 mRNA immunoprecipitated by METTL3 antibody (**P < 0.01 vs. IgG group). D NLRC5 expression in EC form endometrial tissues microarray cohort (scale bar: 100 μm; **P < 0.01 vs. Normal group) and TCGA datasets (*P < 0.05 vs. Normal group). E Kaplan-Meier curves of correlation of NLRC5 with the EC cumulative survival from TCGA datasets (P = 0.01). F Expression correlation between METTL3 and NLRC5 in endometrial tissues microarray cohort by Pearson correlation analysis (R = 0.63, P = 5.9e-12). G The protein and mRNA expressions of NLRC5 in HEC-1 A and HEC-1B cell with or without shMETTL3 (**P < 0.01 vs. shNC group). H The stability of NLRC5 mRNA in HEC-1 A and HEC-1B cell with or without shMETTL3 (**P < 0.01 vs. shNC group). I The protein and mRNA expressions of NLRC5 in Ishikawa cell with or without METTL3 overexpression (**P < 0.01 vs. Vector group). J The stability of NLRC5 mRNA in Ishikawa cell with or without METTL3 overexpression (**P < 0.01 vs. Vector group). K IHC staining of NLRC5 in solid tumor of BALB/C female mice (scale bar: 100 μm; **P < 0.01 vs. Vector group). L YTHDF2 expression in EC form endometrial tissues microarray cohort (scale bar: 100 μm; **P < 0.01 vs. Normal group) and TCGA datasets (*P < 0.05 vs. Normal group). M The protein and mRNA expressions of YTHDF2 in endometria from normal subjects and EC patients (n = 4, **P < 0.01 vs. Normal group). N Kaplan-Meier curves of correlation of YTHDF2 with the EC cumulative survival from TCGA datasets (P = 0.01). O Expression correlation between YTHDF2 and NLRC5 in endometrial tissues microarray cohort by Pearson correlation analysis (R = -0.59, P = 2.2e-10). P RIP-PCR data shows the content of NLRC5 mRNA immunoprecipitated by YTHDF2 antibody (**P < 0.01 vs. IgG group). Q The protein and mRNA expressions of YTHDF2 and NLRC5 in HEC-1B cell with or without YTHDF2 overexpression (**P < 0.01 vs. Vector group). R The stability of NLRC5 mRNA in HEC-1B cell with or without YTHDF2 overexpression (**P < 0.01 vs. Vector group). S The protein and mRNA expressions of YTHDF2 and NLRC5 in HEC-1B cell with or without shYTHDF2 (**P < 0.01 vs. shNC group). T The stability of NLRC5 mRNA in HEC-1B cell with or without shYTHDF2 (**P < 0.01 vs. shNC group). U The protein and mRNA expressions of NLRC5 in HEC-1B cell with or without METTL3 overexpression or METTL3 + YTHDF2 overexpression (**P < 0.01 vs. Vector group, ^##P < 0.01 vs. METTL3 overexpression group). V The stability of NLRC5 mRNA in HEC-1B cell with or without METTL3 overexpression or METTL3 + YTHDF2 overexpression